Antipyretic Drugs for Children Market Report 2024

This Antipyretic Drugs for Children market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The antipyretic drugs for children market size has grown strongly in recent years. It will grow from $3.02 billion in 2023 to $3.21 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth observed during the historic period can be attributed to several factors, including heightened awareness of pediatric health, which has led to increased demand for antipyretic medications. Additionally, there has been a growing incidence of fever-related illnesses in children globally, along with rising healthcare expenditures among families for treating common childhood fevers. Access to over-the-counter antipyretic drugs has also improved in emerging markets, and there is an increasing emphasis on preventive healthcare and early intervention for pediatric fevers.

The antipyretic drugs for children market size is expected to see strong growth in the next few years. It will grow to $4.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth during the forecast period can be attributed to a rising focus on advancements in pediatric healthcare, which is increasing the demand for safer antipyretic drugs. Additionally, the growing prevalence of viral infections in children is fueling the need for antipyretic treatments. There are also increasing government initiatives aimed at improving access to pediatric healthcare in developing countries, along with advances in drug formulations and delivery mechanisms that enhance the efficacy of antipyretics. Furthermore, the expansion of pharmaceutical companies in emerging markets is driving the availability of pediatric medications. Key trends expected during this period include technological innovations in pediatric drug formulations for faster and safer fever relief, a shift towards natural and herbal-based antipyretic drugs for children, an increasing emphasis on personalized treatments for managing fevers, a growing adoption of telemedicine platforms for accessing pediatric consultations related to fever management, and the development of combination antipyretic drugs that target multiple symptoms in children.

The increasing prevalence of viral and bacterial infections is expected to drive growth in the antipyretic drugs market for children in the future. Viral infections occur when viruses invade and replicate within host cells, leading to diseases such as influenza (flu). Bacterial infections arise from harmful bacteria entering the body and multiplying, causing illnesses such as strep throat or tuberculosis. The rise in these infections can be attributed to factors such as growing antibiotic resistance, global travel, and increased population density, which facilitate the spread of pathogens. Antipyretic drugs, including acetaminophen and ibuprofen, are commonly used in children to reduce fever and alleviate discomfort associated with these infections. For example, the Office for National Statistics, a UK-based non-ministerial department, reported that between December 2021 and March 2022, there were 6,898 deaths due to flu and pneumonia in the UK, up from 5,288 deaths in the same period of 2020-2021. This represents an increase of over 1,600 deaths year-over-year. Consequently, the rising incidence of viral and bacterial infections is fueling the growth of the antipyretic drugs market for children.

The increasing birth rates are expected to contribute to the growth of the antipyretic drug market for children. The birth rate refers to the number of live births per 1,000 people in a population each year. This increase can be attributed to better access to healthcare, improved economic conditions, and higher fertility rates in certain regions. A higher birth rate leads to greater demand for antipyretic drugs for children, as a larger population of infants and young children necessitates more medical care, including fever management. For instance, the Registry of Births, Deaths, and Marriages in Victoria, an electronic resource based in Australia, reported that the number of births registered in Victoria rose from 7,689 in July 2024 to 7,994 in August 2024. Therefore, the growing birth rates are driving the antipyretic drug market for children.

Key players in the antipyretic drugs market for children are concentrating on developing advanced drug formulations, such as medicine gummy bites, to improve ease of administration and enhance compliance among young patients. Medicine gummy bites are chewable, gummy medications designed to make taking medicine more appealing, especially for children. They come in various forms and flavors to encourage compliance and simplify the process. For example, in October 2023, DrKids, a US-based pharmaceutical company, launched an acetaminophen gummy bite. This innovative medication provides a child-friendly alternative for pain and fever relief and features an exact dosing system that simplifies medicine administration for parents while ensuring safety and effectiveness.

Major companies operating in the antipyretic drugs for children market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, GlaxoSmithKline plc, Reckitt Benckiser Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Limited, Towa Pharmaceutical Co Ltd, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited.

North America was the largest region in the antipyretic drugs for children market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipyretic drugs for children market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antipyretic drugs for children market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antipyretic drugs for children are medications specifically designed to reduce fever. They function by lowering the body's temperature through various mechanisms, including the inhibition of fever-inducing substances. These drugs help alleviate discomfort and prevent complications related to high fever in children.

The primary classes of antipyretic drugs for children include acetaminophen, ibuprofen, and others. Acetaminophen, also known as paracetamol, is an analgesic and antipyretic medication that provides pain relief and reduces fever without having anti-inflammatory properties. Available dosage forms include tablets, syrups, suppositories, and others, tailored for different age groups, such as newborns, infants, toddlers, and children.

The antipyretic drugs for children market research report is one of a series of new reports that provides antipyretic drugs for children market statistics, including antipyretic drugs for children industry global market size, regional shares, competitors with a antipyretic drugs for children market share, detailed antipyretic drugs for children market segments, market trends and opportunities, and any further data you may need to thrive in the antipyretic drugs for children industry. This antipyretic drugs for children market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antipyretic drugs for children market consists of sales of acetaminophen (tylenol), ibuprofen (advil, motrin), and naproxen (aleve). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.